

**Supplemental Figure S1. Impact of metronomic CPA on tumor blood vessel pericyte coverage.**

Increased pericyte coverage is induced by several anti-angiogenic drugs, prompting us to investigate whether metronomic CPA affects tumor blood vessel pericyte coverage. **Panel A.** Smooth muscle actin- $\alpha$  (blue) and CD31 (brown) double immunostaining identifies 9L tumor blood vessels co-localized with pericytes. Scale bar, 20  $\mu$ m. **Panel B.** In untreated 9L tumors, only ~ 18% of blood vessels were covered by smooth muscle actin  $\alpha$ -positive pericytes. This pericyte coverage was transiently increased on day 3 after the second CPA treatment (day 0 vs. day 9,  $p < 0.01$ , indicated by double asterisks), which coincided with a significant drop in overall tumor microvessel density and may reflect the preferential killing of non-pericyte covered blood vessels during the initial CPA treatment cycles. However, longer-term metronomic CPA treatment did not selectively target pericytes, consistent with the observation that 12-16 wks of continuous CPA treatment has no effect on tumor vessel pericyte coverage (*Pietras and Hanahan, J Clin Oncol 2005;23:939-52*).

